DRUG ABUSE TREATMENT MARKET ANALYSIS

Drug Abuse Treatment Market, By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Global Drug Abuse Treatment Market- Recent Developments

New Product Launches/Approvals:

In May 23, 2023, Braeburn Inc. a pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for BRIXADI (buprenorphine) extended-release injection for subcutaneous use, a new weekly and monthly medication for moderate to severe opioid use disorder.
In November 2022, Tempero Bio, Inc., a clinical-stage biopharmaceutical company received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for TMP-301. TMP-301 is the company's investigational metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) candidate used for treatment in cocaine use disorders (CUD).
On May 16, 2023, Perrigo Company plc. a pharmaceutical company received final approval from the U.S. Food and Drug Administration for nicotine coated mint lozenges, 2 mg and 4 mg over-the-counter (OTC). Nicotine polacrilex lozenges helps to reduce withdrawal symptoms in consumers who are trying to quit smoking.

Acquisition and Collaborations:

In January 2022, Pfizer Inc. a pharmaceutical company collaborated with Alex Therapeutics a digital therapeutics company to form a strategic commercial partnership to use Alex Therapeutics (artificial intelligence) AI-based platform for cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) for nicotine cessation in nicotine-addicted patients.